Cargando…

Epigenetic Impacts of Ascorbate on Human Metastatic Melanoma Cells

In recent years, increasing evidence has emerged demonstrating that high-dose ascorbate bears cytotoxic effects on cancer cells in vitro and in vivo, making ascorbate a pro-oxidative drug that catalyzes hydrogen peroxide production in tissues instead of acting as a radical scavenger. This anticancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Venturelli, Sascha, Sinnberg, Tobias W., Berger, Alexander, Noor, Seema, Levesque, Mitchell Paul, Böcker, Alexander, Niessner, Heike, Lauer, Ulrich M., Bitzer, Michael, Garbe, Claus, Busch, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142417/ https://www.ncbi.nlm.nih.gov/pubmed/25202679 http://dx.doi.org/10.3389/fonc.2014.00227

Ejemplares similares

The ROS-induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF-1alpha in the NCI60 cancer cell lines
por: Sinnberg, Tobias, et al.
Publicado: (2014)

Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo
por: Niessner, Heike, et al.
Publicado: (2022)

High-Dose Ascorbate in Combination with Anti-PD1 Checkpoint Inhibition as Treatment Option for Malignant Melanoma
por: Burkard, Markus, et al.
Publicado: (2023)

Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells
por: Sinnberg, Tobias, et al.
Publicado: (2018)

Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype
por: Sinnberg, Tobias, et al.
Publicado: (2018)

Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma—Old Myth or New Logos?
por: Meraz-Torres, Francisco, et al.
Publicado: (2020)

Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells
por: Venturelli, Sascha, et al.
Publicado: (2013)

Correction: Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells
por: Venturelli, Sascha, et al.
Publicado: (2013)

Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy
por: Schmitt, Marisa, et al.
Publicado: (2021)

Ex Vivo Evaluation of the Sepsis Triple Therapy High-Dose Vitamin C in Combination with Vitamin B1 and Hydrocortisone in a Human Peripheral Blood Mononuclear Cells (PBMCs) Model
por: Lauer, Annie, et al.
Publicado: (2021)

Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs
por: Makino, Elena, et al.
Publicado: (2018)

Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma
por: Mayer, Mascha, et al.
Publicado: (2022)

Relevant Membrane Transport Proteins as Possible Gatekeepers for Effective Pharmacological Ascorbate Treatment in Cancer
por: Leischner, Christian, et al.
Publicado: (2023)

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase
por: Kosnopfel, Corinna, et al.
Publicado: (2017)

An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study
por: Amaral, Teresa, et al.
Publicado: (2020)

Parenteral high-dose ascorbate - A possible approach for the treatment of glioblastoma (Review)
por: Renner, Olga, et al.
Publicado: (2021)

Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients
por: Hilke, Franz J., et al.
Publicado: (2020)

Epigenetic activities of flavonoids in the prevention and treatment of cancer
por: Busch, Christian, et al.
Publicado: (2015)

Tumour Progression Stage-Dependent Secretion of YB-1 Stimulates Melanoma Cell Migration and Invasion
por: Kosnopfel, Corinna, et al.
Publicado: (2020)

Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma
por: Forschner, Andrea, et al.
Publicado: (2021)

Vitamin C Deficiency in Blood Samples of COVID-19 Patients
por: Sinnberg, Tobias, et al.
Publicado: (2022)

MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
por: Forschner, Andrea, et al.
Publicado: (2020)

Comparative Analysis of the Antitumor Activity of Cis- and Trans-Resveratrol in Human Cancer Cells with Different p53 Status
por: Leischner, Christian, et al.
Publicado: (2021)

Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?
por: Amaral, Teresa, et al.
Publicado: (2020)

Selective Protection of Human Liver Tissue in TNF-Targeting of Cancers of the Liver by Transient Depletion of Adenosine Triphosphate
por: Weiland, Timo, et al.
Publicado: (2012)

Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition
por: Schmitt, Marisa, et al.
Publicado: (2021)

Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition
por: Makino, Elena, et al.
Publicado: (2020)

A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib
por: Sinnberg, Tobias, et al.
Publicado: (2016)

β-Catenin Signaling Increases during Melanoma Progression and Promotes Tumor Cell Survival and Chemoresistance
por: Sinnberg, Tobias, et al.
Publicado: (2011)

PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo
por: Fröhlich, Lisa Marie, et al.
Publicado: (2023)

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases
por: Niessner, Heike, et al.
Publicado: (2013)

Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases
por: Chatziioannou, Eftychia, et al.
Publicado: (2023)

Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors – Results of a Prospective Biomarker Study
por: Forschner, Andrea, et al.
Publicado: (2020)

Epigenetic effects of pharmacologic ascorbate
por: Steers, Garett J., et al.
Publicado: (2021)

Nutritional immunology: function of natural killer cells and their modulation by resveratrol for cancer prevention and treatment
por: Leischner, Christian, et al.
Publicado: (2016)

Systematic Review of Gossypol/AT-101 in Cancer Clinical Trials
por: Renner, Olga, et al.
Publicado: (2022)

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
por: Bochem, Jonas, et al.
Publicado: (2021)

Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion
por: Kosnopfel, Corinna, et al.
Publicado: (2023)

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy
por: Chatziioannou, Eftychia, et al.
Publicado: (2023)

Determination of phage load and administration time in simulated occurrences of antibacterial treatments
por: Plunder, Steffen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s5jj8qq5gfbs802vk23n7dvttp